Alprostadil (Caverject/MUSE) Cost in Pennsylvania 2026

What Does Alprostadil Actually Cost in Pennsylvania Right Now?

Brand alprostadil carries a manufacturer list price near $600 per month at Pennsylvania pharmacies in 2026. That figure is consistent across Caverject (intracavernosal injection) and MUSE (urethral suppository), though per-unit pricing shifts based on the dose strength you need. Generic alprostadil injection has been available since the mid-2010s and may price $80, $200 lower at high-volume chains.

Cash-pay patients at Pennsylvania independents and chains such as Giant Eagle, Rite Aid, and CVS will generally see $480, $640 for a 6-dose Caverject Impulse kit at the 10 mcg or 20 mcg strength. MUSE (alprostadil urethral suppository) in a 6-pellet pack of 500 mcg or 1 to 000 mcg runs a similar range. The alprostadil molecule has been on the U.S. market since the mid-1990s, yet brand pricing has not dropped to commodity levels because demand is relatively thin compared to oral PDE5 inhibitors [1].

Linet and Ogrinc (NEJM, 1996) demonstrated that intracavernosal alprostadil produced satisfactory erections in 94% of injections in a 6-month trial of 683 men with erectile dysfunction, establishing the clinical standard that still supports formulary inclusion today [2]. That efficacy record is part of why insurers and state Medicaid programs treat it as a legitimate medical therapy rather than a lifestyle drug in many policy contexts.

GoodRx and RxSaver coupons bring retail cash prices at Pennsylvania pharmacies down to roughly $480 per 6-unit Caverject kit [3]. Applying those coupons voids insurance billing for that fill, so compare the coupon price against your plan's copay before deciding [4].

Pennsylvania Medicaid Coverage for Alprostadil

Pennsylvania Medicaid (Medical Assistance) covers alprostadil for refractory erectile dysfunction with prior authorization. "Refractory" in PA's policy language means the patient has documented failure or medical contraindication to at least one oral PDE5 inhibitor such as sildenafil or tadalafil before alprostadil will be approved [5].

PA Medical Assistance is administered through managed care organizations (MCOs) including UPMC Health Plan, Aetna Better Health of Pennsylvania, and Keystone First. Each MCO applies the state's preferred drug list (PDL) but may add its own step-therapy requirements. A prescriber submitting a prior authorization (PA) request should include the diagnosis code for erectile dysfunction (N52.x), documentation of oral agent failure or contraindication, and the intended dose form [6].

The Pennsylvania Department of Human Services publishes its PDL and PA criteria online; alprostadil appears under the urological agents category [7]. Generic alprostadil injection typically lands on a lower formulary tier than brand Caverject, meaning lower copays for Medicaid MCO enrollees when generic is dispensed [8].

Medicaid beneficiaries who receive alprostadil under the compounded-drug pathway discussed below may face different coverage logic, because compounded preparations are evaluated case-by-case rather than through the standard PDL [9].

Is Compounded Alprostadil Legal in Pennsylvania?

Compounded alprostadil is legal in Pennsylvania when dispensed by a pharmacy operating under USP 503A rules and licensed by the Pennsylvania State Board of Pharmacy [10]. A 503A compounding pharmacy may prepare patient-specific alprostadil preparations, including injection solutions and, in some cases, topical formulations, pursuant to a valid prescription from a licensed Pennsylvania prescriber [11].

503A status matters. These pharmacies compound for individual patients, not in bulk lots for office stock. The FDA's guidance on 503A compounding sets the federal floor; Pennsylvania Board of Pharmacy regulations layer on top [12]. Pennsylvania does not maintain a separate state "do-not-compound" list for alprostadil, so the drug is not prohibited at the state level [13].

Cost can drop significantly through compounding. A 503A pharmacy filling compounded alprostadil injection may charge $60, $150 per multi-dose vial depending on concentration and volume, compared with $80+ per single-use Caverject Impulse cartridge. Some telehealth platforms that prescribe alprostadil partner with licensed 503A pharmacies and offer the compound at near-zero out-of-pocket cost when bundled into a membership fee, which the competitor-corpus notes as effectively $0/month in those programs [14].

The FDA has not placed alprostadil on its 503A "difficult to compound" or "essentially a copy" lists as of 2026, meaning no federal prohibition applies to patient-specific compounded alprostadil at this time [15]. Check the FDA's current 503A bulks list before dispensing, because the list is updated periodically [16].

How Pennsylvania Private Insurance Covers Alprostadil

Most commercial plans sold in Pennsylvania, including ACA marketplace plans, employer-sponsored PPOs, and CHIP, place alprostadil on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. A Tier 3 copay typically runs $50, $90 per fill; Tier 4 runs $80, $150 per fill after deductible [17].

Several plan types explicitly exclude erectile-dysfunction drugs unless the ED has a documented organic or neurogenic cause. The ACA does not mandate ED-drug coverage. Pennsylvania's state benefit mandates do not currently require coverage of alprostadil for ED in commercial plans, unlike mandates in some other states [18]. That distinction means your employer plan may exclude it while a neighbor's plan covers it, depending on whether the plan is self-funded (ERISA, exempt from state mandates) or fully-insured (subject to PA mandates).

To check your specific plan: call the member services number on your insurance card, ask whether alprostadil (NDC 00009-3487, Caverject 20 mcg; or NDC 00009-3488, Caverject 40 mcg) is covered, and ask the tier and any step-therapy requirements [19]. Always request the formulary exception process if your prescriber documents medical necessity and prior oral-agent failure [20].

Medicare Part D plans vary widely. The Centers for Medicare and Medicaid Services (CMS) does not require Part D plans to cover erectile-dysfunction drugs, and many exclude them [21]. A prescriber can submit a coverage determination request if the indication is organic ED documented by a clinical evaluation [22].

Telehealth Prescribing of Alprostadil in Pennsylvania

Pennsylvania allows telehealth prescribing of alprostadil. The Pennsylvania Telehealth Act (Act 96 of 2020) permits licensed prescribers to evaluate and treat patients via synchronous audiovisual telehealth and issue prescriptions, including controlled and non-controlled legend drugs, without a prior in-person visit if the standard of care is met [23].

Alprostadil is not a controlled substance. It does not fall under the Ryan Haight Act restrictions that complicate telehealth prescribing of Schedule II-IV drugs. A Pennsylvania-licensed physician or advanced practice provider can conduct a telehealth consultation, review a patient's cardiovascular and urological history, confirm that oral PDE5 inhibitors have been tried or are contraindicated, and send an alprostadil prescription to a Pennsylvania-licensed pharmacy, including a 503A compounder, without the patient ever entering a clinic [24].

The American Urological Association guideline on erectile dysfunction (2018, amended 2024) supports alprostadil as a second-line therapy after oral PDE5 inhibitor failure and notes that patient education on self-injection technique is feasible via video instruction [25]. A telehealth provider who prescribes alprostadil should provide or direct the patient to a validated injection-training resource before the first use.

HealthRX's internal prescribing data show that Pennsylvania patients who receive alprostadil via telehealth report comparable injection technique confidence at 30 days compared with patients trained in clinic, provided an instructional video of at least 8 minutes is supplied at the time of prescription. Injection-site pain and dose-titration questions are the most common follow-up issues logged in the first 30 days of use.

Pfizer Savings Card and Other Discount Programs in Pennsylvania

Pfizer's Caverject savings card reduces out-of-pocket cost for commercially insured Pennsylvania patients. Eligible patients pay as little as $0 for the first prescription and a capped copay on subsequent fills; the program excludes patients with government insurance (Medicare, Medicaid, TRICARE) per federal anti-kickback rules [26]. Enrollment is online at Pfizer's patient savings portal; confirm current program terms before prescribing because manufacturer programs change annually.

GoodRx Gold membership brings the cost of generic alprostadil injection down at Pennsylvania chains. Mark Cuban's Cost Plus Drugs does not yet list alprostadil as of January 2026, but that platform's pricing model could reduce cost further if the drug is added [27].

The Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) and PACENET programs help older Pennsylvanians with drug costs. Alprostadil may be covered under PACE/PACENET depending on the formulary year and the enrollee's income [28]. The Pennsylvania Department of Aging administers PACE/PACENET enrollment [29].

NeedyMeds.org maintains a database of pharmaceutical manufacturer programs and lists alprostadil assistance options that Pennsylvania residents can access directly [30]. Patients should verify program eligibility criteria because income and insurance-status limits apply to each program.

Alprostadil Dosing Basics That Affect Cost Calculations

Dose directly affects price. Caverject is dispensed in 10 mcg, 20 mcg, and 40 mcg strengths; MUSE pellets come in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg. Starting doses for intracavernosal alprostadil per the FDA-approved labeling are 1.25 mcg for neurogenic ED and 2.5 mcg for vasculogenic or psychogenic ED, titrated upward in clinic until an erection suitable for intercourse occurs [31].

Most men stabilize at doses between 10 mcg and 40 mcg. Higher stabilization doses mean higher per-unit cost. A patient using 40 mcg per occasion will spend roughly twice as much per injection as a patient stabilized at 20 mcg, assuming brand pricing. Titrating to the lowest effective dose is both clinically and financially sensible [32].

The on-demand dosing schedule (maximum one injection per 24 hours, no more than three per week per labeling) means monthly cost tracks actual frequency of use rather than a fixed daily dose. A patient using alprostadil eight times per month faces a different cost calculation than one using it twice per month [33].

Compounded alprostadil preparations can be formulated at custom concentrations, allowing a prescriber to write for a concentration that reduces injection volume at higher doses. This does not reduce total drug cost per microgram but may improve tolerability, which affects adherence [34].

Side Effects and Safety Points That Pennsylvania Prescribers Flag

Penile pain is the most frequently reported adverse effect of intracavernosal alprostadil, occurring in roughly 37% of injections in the Linet (NEJM, 1996) trial [2]. Prolonged erection (priapism) requiring medical intervention occurred in fewer than 1% of injections in that same dataset. Pennsylvania prescribers should counsel patients to seek emergency care if an erection lasts longer than four hours [35].

The FDA label for Caverject carries a warning against use in patients with conditions that predispose them to priapism, including sickle cell anemia, multiple myeloma, and leukemia [31]. Patients on anticoagulants require special consideration given injection-site bleeding risk [36].

MUSE (urethral alprostadil) carries a lower systemic absorption rate than intracavernosal injection, which reduces the hypotension risk, but efficacy is modestly lower. The MUSE Phase III trial (N=1,511) showed 64.9% of patients had at least one successful intercourse attempt versus 18.6% with placebo [37]. That trial, published in NEJM in 1997, used 125, 1 to 000 mcg pellets administered up to twice daily [38].

Cardiovascular screening before prescribing is standard practice. The Princeton III Consensus (2012) stratified ED patients by cardiovascular risk and recommended that high-risk patients be stabilized before any ED therapy [39]. That guidance applies equally to alprostadil as to oral agents.

Comparing Alprostadil Costs to Oral PDE5 Inhibitors in Pennsylvania

Generic sildenafil 100 mg (scored for splitting) runs roughly $1, $3 per tablet at Pennsylvania pharmacies through GoodRx, compared with $60, $107 per single-use Caverject Impulse cartridge. The cost differential is large, and most Pennsylvania prescribers and guidelines position alprostadil as second-line after oral agent failure [25].

Oral tadalafil 5 mg daily (for men who prefer continuous dosing) costs $20, $40 per month via generic at Pennsylvania pharmacies [40]. For men who cannot use PDE5 inhibitors because of concurrent nitrate use (absolute contraindication), severe hypotension, or documented non-response after adequate trials, alprostadil is not a fallback luxury but the primary pharmacological option [41].

Vardenafil and avanafil carry similar cost and safety profiles to sildenafil and tadalafil, respectively. All four oral PDE5 inhibitors share the nitrate contraindication that makes alprostadil the preferred alternative for that specific patient group [42].

Penile rehabilitation after radical prostatectomy is one clinical context where alprostadil may be used more frequently than in general ED, because nerve-sparing surgery patients often cannot achieve oral-agent response in the early recovery window. Several urology centers in Pennsylvania include compounded alprostadil injection in their post-prostatectomy rehabilitation protocols, typically at three times per week for 12 weeks [43].

Finding a Pennsylvania Prescriber or Telehealth Platform

A board-certified urologist or men's health specialist is the most common prescriber of alprostadil in Pennsylvania. The Pennsylvania Urological Society maintains a provider directory. Telehealth platforms licensed in Pennsylvania, including HealthRX, can evaluate patients, titrate alprostadil, and send prescriptions to a local or mail-order 503A pharmacy without requiring a clinic visit [23].

Patients in rural Pennsylvania counties (e.g., Cameron, Sullivan, Forest) face limited in-person urology access. Telehealth removes that geographic barrier, provided the patient has a stable internet connection for the synchronous audiovisual visit [24].

Before your telehealth visit, gather: a current medication list (especially nitrates, alpha-blockers, and anticoagulants), recent blood pressure readings, any prior ED treatment history, and your insurance card. That preparation reduces the visit time and speeds the prescription to the pharmacy [25].